CN118320239A - Atomization equipment for improving deposition rate and atomization equipment control method - Google Patents

Abstract

The application provides an atomization device for improving a deposition rate and an atomization device control method, wherein the atomization device for improving the deposition rate can be switched between an inhalation mode and an exhalation mode, and comprises an air chamber, an atomization device, a switching valve and an airflow generator, wherein the air chamber comprises a first air chamber and a second air chamber, the first air chamber is communicated with the second air chamber through an air inlet channel, the first air chamber is communicated with a user through an air outlet channel, the atomization device is communicated with the second air chamber, the atomization device is used for supplying air carrying aerosol to the second air chamber, the switching valve is configured to enable the air inlet channel to be opened and the air outlet channel to be closed in the exhalation mode, the air inlet channel to be closed and the air outlet channel to be opened in the inhalation mode, the airflow generator drives the first air chamber to enter air from the second air chamber in the exhalation mode, and the airflow generator drives the first air chamber to be set to be positively discharged to the user. The atomizing device and the atomizing device control method for improving the deposition rate can improve the deposition rate of aerosol.

Description

Atomization equipment for improving deposition rate and atomization equipment control method

Technical Field

The application relates to the field of atomization of atomizers, in particular to atomization equipment for improving deposition rate and an atomization equipment control method.

Background

Aerosol inhalation is to prepare aerosol from bronchodilators, hormones, antibacterial drugs, humidifying liquid and other solutions in an aerosol mode, and convey the aerosol into the airway and the lung, so that the requirements of treatment purposes or non-treatment purposes are met.

Theoretically, bronchiectasis occurs mostly in the peripheral airways. In the normal inhalation state, the airflow speed of the air gradually decreases from the large air passage to the small air passage, and the airflow speed further remarkably decreases from the small air passage to the expanded small air passage, so that the airflow is difficult to reach the expanded bronchi, and the aerosol is difficult to deposit in the expanded bronchi. In addition, the phenomena of sputum blockage, airway wall inflammation and the like exist in the expanded bronchus lumen, and the deposition of inhaled aerosol in the expanded bronchus is further hindered.

It has thus been found in practice that for users with symptoms of bronchiectasis, the deposition of aerosols is mainly concentrated in the normal, unexpanded bronchi and their dominant lung fields, with little or no distribution in the expanded bronchi and their dominant lung fields, resulting in an insufficient uniformity of aerosol deposition, a very low rate of aerosol deposition in the expanded bronchi, and poor use of conventional nebulizing devices currently in clinical use.

Non-invasive positive airway pressure (CPAP) includes Continuous Positive Airway Pressure (CPAP) and bi-level positive airway pressure (BiPAP), which are commonly used clinically for the intervention and alleviation of Chronic Obstructive Pulmonary Disease (COPD), obstructive Sleep Apnea (OSA), and other airway related symptoms, which effectively open the airway by applying positive pressure, thereby reducing the user's respiratory effort. Wherein CPAP is maintained at a constant pressure throughout the breathing cycle, while BiPAP applies a high level of inspiratory positive pressure (IPAP) upon inhalation and a low level of Expiratory Positive Airway Pressure (EPAP) upon exhalation.

In some related art nebulizers are connected to positive pressure ventilators, nebulized inhalation is used in combination with non-invasive positive pressure ventilation in an effort to cause more adequate deposition of aerosol to the dilated bronchi by opening the airway with positive pressure. In the research, the effect of aerosol deposition in the lung of the atomization technology is observed by adopting an isotope tracing technology, and the result shows that the deposition effect is not ideal, but the deposition rate is not increased and reduced, and is lower than that of the common atomization mode.

Invasive positive pressure mechanical ventilation also often requires access to a nebulizer in the tubing for nebulizing treatment of the patient. However, our research data suggests that this nebulization mode of directly connecting the nebulizer to the ventilator circuit is not effective in delivering nebulized drug into the patient's lungs, which is instead less sedimentary than the normal nebulization mode.

In COPD patients, studies have also found that the conventional nebulization pattern, biPAP or nebulization pattern with an invasive positive airway pressure connected nebulizer, the drug deposition rate in the diseased lung fields such as emphysema, lung bulla, etc. is low, which makes the drug incapable of exerting an optimal therapeutic effect.

In combination, aerosol deposition rate at the lesion site of the distal airway (the dilated bronchus of patients with bronchiectasis or the emphysema lung bulla site of COPD patients) is not ideal by adopting the aerosol inhalation and positive pressure ventilation combined scheme in the related art.

Disclosure of Invention

The present application aims to solve at least one of the technical problems existing in the prior art. Therefore, the application provides an atomization device and an atomization device control method for improving the deposition rate, which can improve the deposition rate of aerosol in a lesion part of a distal airway.

According to the present application, there is provided an atomizing apparatus for increasing a deposition rate, capable of switching between an inhalation mode and an exhalation mode, comprising: the device comprises an air chamber, an atomization device, a switching valve and an air flow generator, wherein the air chamber comprises a first air chamber and a second air chamber, the first air chamber is communicated with the second air chamber through an air inlet channel, the first air chamber is communicated with a user through an air outlet channel, the atomization device is communicated with the second air chamber, the atomization device is used for supplying air carrying aerosol to the second air chamber, the switching valve is configured to enable the air inlet channel to be opened and the air outlet channel to be closed in an expiration mode, enable the air inlet channel to be closed and the air outlet channel to be opened in an inspiration mode, the air flow generator is communicated with the first air chamber, the air flow generator drives the first air chamber to inlet air from the second air chamber in the expiration mode, and the air flow generator drives the first air chamber to set positive pressure to supply air to the user in the inspiration mode.

According to some embodiments of the application, the deposition rate enhancing nebulizing device comprises a breath sensor arranged at an outlet of the exhaust channel for detecting a breathing state of the user for allowing the deposition rate enhancing nebulizing device to switch between an inhalation mode and an exhalation mode in response to the breathing state.

According to some embodiments of the application, the switching valve includes a first solenoid valve provided in the exhaust passage and a second solenoid valve provided in the intake passage.

According to some embodiments of the application, the airflow generator includes a piston chamber and a piston rod disposed in the piston chamber that reciprocates to drive the first air chamber to inhale and exhale.

According to some embodiments of the application, the atomization device for increasing the deposition rate comprises a mist storage bag, wherein the mist storage bag is communicated with the second air chamber, and the volume of the mist storage bag can be increased and decreased along with the pressure change so as to keep the pressure of the second air chamber stable.

According to some embodiments of the application, the aerosol produced by the atomizing device has a median particle size of 1-5 μm.

According to some embodiments of the application, the atomizing device is a vibrating mesh atomizer, a jet atomizer, or an ultrasonic atomizer.

According to some embodiments of the application, the deposition rate increasing atomizing device is provided with a plurality of atomizing devices in parallel.

According to the atomization device control method provided by the application, the atomization device for improving the deposition rate provided by the application is controlled, and the atomization device control method comprises the following steps: the atomizing device atomizes and generates aerosol; in response to exhalation by a user, the increased deposition rate aerosolization apparatus switches to the exhalation mode, the first gas chamber capturing aerosol-carrying gas from the second gas chamber; in response to a user inhaling, the deposition rate enhancing atomizing apparatus switches to the inhaling mode, the first plenum being configured to deliver aerosol-carrying gas to the user in a positive pressure.

According to some embodiments of the application, the set positive pressure is less than or equal to a maximum inspiratory pressure of the user.

According to some embodiments of the application, the method further comprises measuring a maximum inhalation pressure of the user.

According to some embodiments of the application, the set positive pressure is gradually increased from an initial value to a plateau value over a plurality of respiratory cycles.

According to some embodiments of the application, the plateau value is set to any of 10cmH ₂ O to 20cmH ₂ O.

According to some embodiments of the application, the initial value is set to any of 4cmH ₂ O to 8cmH ₂ O.

According to some embodiments of the application, the set positive pressure increases by a set magnitude, the tolerability is determined after each inhalation, and increases again after the user establishes tolerance to the current pressure.

According to some embodiments of the application, the inhalation mode has a duration of 3s to 5s during one respiratory cycle.

The atomization device for improving the deposition rate provided by the application has at least the following technical effects:

by supplying air to the user under positive pressure, the air passage of the user can be opened, and aerosol is promoted to be more fully deposited on the lesion part of the distal air passage;

By closing the air inlet channel in the air suction mode, the pressure rise of the second air chamber can be avoided, so that the generation of aerosol is not influenced by positive pressure ventilation, and the atomizing device is ensured to stably form aerosol;

The aerosol atomized in the inspiration mode is stored in the second air chamber, and the aerosol in the second air chamber and the aerosol newly generated by the atomization device in the expiration mode are fed into the first air chamber together, so that the atomization device is prevented from being started and stopped frequently, and the atomization device is further helped to form the aerosol stably;

By closing the exhaust channel in the expiration mode, the defect that aerosol is lost when a user exhales is overcome, and the waste of the aerosol is avoided;

by setting the time of the inspiration mode to 3s-5s, the user is guided to perform deep and slow inspiration for 3s-5s in a matching way, so that gentle airflow is formed, the airflow can be promoted to further enter the far-end airway, and the aerosol is more fully deposited on the lesion part of the far-end airway;

Therefore, the atomization device for improving the deposition rate can improve the deposition rate of the aerosol at the lesion part of the far-end airway, avoid the waste of the aerosol, improve the utilization rate of medicines and the effective administration time when being used for administration, reduce the treatment cost and greatly improve the treatment effect.

The atomization device control method provided by the application is based on the atomization device for improving the deposition rate, so that the atomization device for improving the deposition rate has the beneficial effects.

In addition, the control method of the atomizing device can prevent the air flow from forming turbulence in the oral cavity and the air passage by limiting the set positive pressure not to exceed the maximum inhalation pressure of a user, prevent the aerosol from being deposited in the oral cavity or the large air passage, and better promote the aerosol to be deposited in the small air passage and the alveoli; by gradually increasing the set positive pressure, the device can help a user to gradually build tolerance to the positive pressure state, avoid unconscious collision of the throat part of the user during inspiration, further avoid turbulent flow of air flow in the oral cavity and the air channel, and further promote aerosol deposition in the small air channel and the alveoli.

Drawings

The foregoing and/or additional aspects and advantages of the application will become apparent and may be better understood from the following description of embodiments taken in conjunction with the accompanying drawings in which:

FIG. 1 is a schematic diagram of a deposition rate enhancing atomizing apparatus according to some embodiments of the present disclosure, showing the deposition rate enhancing atomizing apparatus in an exhalation mode;

FIG. 2 is a schematic diagram of a deposition rate enhancing atomizing apparatus according to some embodiments of the present disclosure, showing the deposition rate enhancing atomizing apparatus in an inhalation mode;

FIG. 3 is a flow chart of an atomizing device control method according to some embodiments of the present disclosure;

FIG. 4 is a schematic flow chart of a method of controlling an atomizing apparatus according to further embodiments of the present application;

FIG. 5 is a developed schematic of the experimental results of example 1 of the present application, showing the orientation using AP-LR;

FIG. 6 is a developed schematic of the experimental results of example 2 of the present application, showing the orientation using AP-LR;

FIG. 7 is a developed schematic of the experimental results of example 3 of the present application, showing the orientation using AP-LR;

FIG. 8 is a development schematic of the experimental results of example 4 of the present application;

FIG. 9 is a development schematic of the experimental results of example 5 of the present application;

FIG. 10 is a schematic development of the experimental results of example 6 of the present application.

Reference numerals:

The atomization device 110, the airflow generator 120, the piston chamber 121, the piston rod 122, the mist storage bag 130, the switching valve 140, the respiration sensor 150, the first air chamber 210, and the second air chamber 220.

Detailed Description

Embodiments of the present application are described in detail below, examples of which are illustrated in the accompanying drawings, wherein like or similar reference numerals refer to like or similar elements or elements having like or similar functions throughout. The embodiments described below by referring to the drawings are illustrative only and are not to be construed as limiting the application.

In the description of the present application, it should be understood that references to orientation descriptions such as upper, lower, front, rear, left, right, etc. are based on the orientation or positional relationship shown in the drawings, are merely for convenience of description of the present application and to simplify the description, and do not indicate or imply that the apparatus or elements referred to must have a particular orientation, be constructed and operated in a particular orientation, and thus should not be construed as limiting the present application.

In the description of the present application, a number means one or more, a number means two or more, and greater than, less than, exceeding, etc. are understood to not include the present number, and above, below, within, etc. are understood to include the present number. The description of the first and second is for the purpose of distinguishing between technical features only and should not be construed as indicating or implying relative importance or implicitly indicating the number of technical features indicated or implicitly indicating the precedence of the technical features indicated.

In the description of the present application, unless explicitly defined otherwise, terms such as arrangement, installation, connection, etc. should be construed broadly and the specific meaning of the terms in the present application can be reasonably determined by a person skilled in the art in combination with the specific contents of the technical scheme.

Nebulizing devices (such as vibrating mesh nebulizers, jet nebulizers, ultrasonic nebulizers, and the like) are used to deliver a medical solution or other solutions to the respiratory system in the form of aerosols, and the deposition distribution of the aerosols in the respiratory system is a key indicator for evaluating the effectiveness of nebulization inhalation. In theory, aerosol inhaled by atomization can be uniformly distributed at different parts of the airway, and the aerosol directly acts on the airway, so that the aerosol can rapidly and efficiently act, and the dosage of the aerosol is obviously reduced compared with systemic intravenous administration when the aerosol is used for treatment, and the systemic adverse reaction is obviously weakened.

Bronchiectasis occurs mostly in the bronchi or bronchioles. In the normal inhalation state, the airflow speed of the air from the large air passage to the small air passage gradually decreases, and compared with the normal bronchi, the airflow in the expanded bronchioles decreases more remarkably. Thus, in the conventional ventilation mode, the air flow is difficult to reach the dilated bronchi, and thus the aerosol of the medical liquid generated by the atomizing device is difficult to deposit in the dilated bronchi. In addition, the phenomena of sputum blockage, airway wall inflammation and the like exist in the expanded bronchus lumen, and the deposition of inhaled aerosol in the expanded bronchus is further hindered.

According to the application, the atomization effect of a traditional atomization device (including jet atomization, ultrasonic atomization and vibration sieve mesh atomization) is observed through an isotope labeling aerosol method, and as a result, aerosol deposition is mainly concentrated on normal and unexpanded bronchi and the dominant lung fields thereof, and the aerosol deposition is not uniform enough due to little or even no distribution of the expanded bronchi and the dominant lung fields thereof, so that the aerosol distribution condition is not as good as expected, and the use effect of the atomization device is not good. In the case of aerosol inhalation treatment, a medicinal liquid deposited in an unexpanded bronchus is required to act on the expanded bronchus (lesion site) by the action of blood circulation, and may affect the efficacy of aerosol inhalation treatment.

In some current clinical practice, aerosol inhalation is sometimes used in combination with positive pressure ventilation, which opens the airways to promote aerosol deposition in the bronchi and lungs (or distal airways). However, it is also noted in experiments that the deposition rate of the medicinal liquid in the dilated bronchi (i.e. the lesion of the distal airway) cannot be well improved by adopting the positive airway pressure modes such as Continuous Positive Airway Pressure (CPAP), bi-level positive airway pressure (BiPAP), continuous high-frequency oscillation ventilation (HFOV) and the like, and the deposition rate is not increased and reduced.

Through experimental analysis, the application obtains:

First, in the related art, the atomization device is commonly connected to a positive pressure ventilator (such as an invasive ventilator, a CPAP device, a BiPAP device, an HFOV device, etc.), but positive pressure airflow generated by the positive pressure ventilator also acts on the atomization device, so as to block the generation of aerosol, and prevent the deposition rate of the aerosol in the lung from increasing and decreasing.

Second, invasive ventilator, CPAP, biPAP, HFOV and other devices commonly deliver gas at high rates of positive pressure, which tend to create turbulence in the throat, causing the aerosol carried by the gas to collide and deposit, making it difficult for the aerosol to be delivered to the lungs.

Finally, the positive pressure ventilation is different from the normal respiratory state of the human body, so that the positive pressure ventilation in one step can lead to poor tolerance of the user, difficult matching and easy involuntary contradiction action, thereby leading the aerosol to be difficult to be conveyed to the lung.

The above factors are combined together to exacerbate the decline in deposition rate after aerosol inhalation and positive airway pressure are combined.

In addition, when the user exhales, aerosols containing the drug are continuously generated in the nebulizer and cannot be delivered to the patient's lungs, and can also result in wastage of the drug.

To this end, embodiments of the present application provide an aerosolization device that increases the deposition rate of aerosols in the whole lung, particularly in diseased regions of the distal airways (e.g., dilated bronchi). The embodiment of the application also provides an atomization device control method used in combination with the atomization device for improving the deposition rate.

Fig. 1 and 2 are block diagrams of an atomizing apparatus for increasing a deposition rate in some embodiments of the present application, and fig. 3 illustrates steps of implementation of a method for controlling an atomizing apparatus in some embodiments of the present application.

Referring to fig. 1 and 2, the present application provides an atomization apparatus for increasing a deposition rate capable of switching between an inhalation mode (fig. 2) and an exhalation mode (fig. 1).

The atomizing apparatus for increasing the deposition rate includes at least a gas chamber, an atomizing device 110, a switching valve 140, and a gas flow generator 120. Wherein the air cells include a first air cell 210 and a second air cell 220, the first air cell 210 is communicated with the second air cell 220 through an air inlet channel, the first air cell 210 is communicated with a user through an air outlet channel, the atomizing device 110 is communicated with the second air cell 220, the atomizing device 110 is used for supplying air carrying aerosol to the second air cell 220, the switching valve 140 is configured to open the air inlet channel and close the air outlet channel in an air inlet mode, close the air inlet channel and open the air outlet channel in an air inlet mode, the air flow generator 120 is communicated with the first air cell 210, the air flow generator 120 drives the first air cell 210 to feed air from the second air cell 220 in an air inlet mode, and the air flow generator 120 drives the first air cell 210 to set positive pressure to feed air to the user in the air inlet mode.

With continued reference to fig. 3, the atomizing device control method may include:

Step S310: the atomizing device 110 atomizes and generates an aerosol.

Step S320: in response to the user exhaling, the aerosolization apparatus that increases the deposition rate switches to an exhalation mode, with the first gas chamber 210 capturing aerosol-carrying gas from the second gas chamber 220.

Step S330: in response to a user inhaling, the aerosolization apparatus that increases the deposition rate switches to an inhaling mode, the first plenum 210 to set the positive pressure to deliver aerosol-carrying gas to the user.

The atomization equipment for improving the deposition rate can help to open the airway of a user by exhausting air to the user under positive pressure, so that aerosol is promoted to be more fully deposited on the expanded bronchus; by closing the air intake passage in the air suction mode, the pressure rise of the second air chamber 220 can be avoided, so that the generation of aerosol is not affected by positive pressure air, ensuring that the atomizing device 110 stably forms aerosol; by storing the aerosol atomized in the inhalation mode in the second air chamber 220, and feeding the aerosol in the second air chamber 220 and the aerosol newly generated by the atomizing device 110 into the first air chamber 210 in the exhalation mode, frequent start and stop of the atomizing device 110 can be avoided, and the atomizing device 110 is further facilitated to stably form the aerosol; by closing the exhaust channel in the exhalation mode, the defect that aerosol is lost when a user exhales is overcome, and the waste of the aerosol is avoided.

Therefore, the atomization device for improving the deposition rate can improve the deposition rate of aerosol in the whole lung, particularly in the lesion parts of the distal airway (such as the parts of the expanded bronchus or the pulmonary emphysema, the lung bulla and the like of COPD) and avoid the waste of the aerosol.

Based on the atomization device control method provided by the application, the atomization device control method at least has the beneficial effects brought by the atomization device for improving the deposition rate. And will not be described in detail herein.

The atomization device for improving the deposition rate of the present application may be a single device used alone or may be a functional module integrated into a medical device, which is not particularly limited in the present application. It should be noted that, in addition to the use of nebulized drug solution, the nebulizing device and the control method of the nebulizing device according to the present application for improving the deposition rate can of course also be used for non-therapeutic purposes, such as supplying water to the airways by nebulizing the physiological saline, thereby making the user breathe more comfortably, etc.

It will be appreciated that the atomising device to increase the deposition rate may be switched between inhalation and exhalation modes on a manual or automatic basis. The manual mode means that a user manually operates the atomizing device according to the breathing state of the user, and the automatic mode means that the atomizing device for improving the deposition rate can detect the breathing state of the user and switch based on the breathing state.

For example, in the manual mode, the switching valve 140 may use a one-way valve capable of being opened or closed based on a change in pressure difference, the two switching valves 140 are respectively provided at the intake passage and the exhaust passage, the switching valve 140 of the intake passage can be opened only to the first air chamber 210 side, and the switching valve 140 of the exhaust passage can be opened only to the user side.

When a user inhales, the airflow generator 120 is manually operated to generate positive pressure airflow, the switching valve 140 of the exhaust channel is opened and the switching valve 140 of the air inlet channel is closed under the action of pressure difference, and the atomization device for improving the deposition rate enters an inhalation mode; when a user exhales, the airflow generator 120 is manually operated to generate negative pressure airflow, the switching valve 140 of the exhaust channel is closed and the switching valve 140 of the air inlet channel is opened under the action of pressure difference, and the atomization device for improving the deposition rate enters an expiration mode.

However, the manual switching is dependent on the reaction and operation of the user, so that the problem that the inhalation mode and the exhalation mode cannot be accurately aligned with the inhalation state and the exhalation state easily occurs, and the deposition effect of the aerosol is affected.

To this end, alternatively, referring to fig. 1 and 2, the deposition rate-increasing atomizing apparatus may include a respiration sensor 150 provided at an outlet of the exhaust passage, the respiration sensor 150 for detecting a respiration state of a user to allow the deposition rate-increasing atomizing apparatus to switch between an inhalation mode and an exhalation mode in response to the respiration state, thereby achieving automatic mode switching, contributing to an increase in deposition effect of aerosol.

In response, the switching valve 140 may use a solenoid valve, and the switching valve 140 is communicatively connected to the respiration sensor 150 so as to be opened and closed based on the signal of the respiration sensor 150. Illustratively, the switching valve 140 may include a first solenoid valve disposed in the exhaust passage and a second solenoid valve disposed in the intake passage, which are alternately opened and closed according to a signal of the respiration sensor 150, and in fig. 1 and 2, the switching valve 140 is shown in an opened state by a dotted line and the switching valve 140 is shown in a closed state by a solid line.

Of course, the electromagnetic valve may also use a three-way electromagnetic valve, and at this time, the exhaust passage and the intake passage are communicated with the first air chamber 210 through the same air port, and the on-off state of the exhaust passage and the intake passage is controlled simultaneously by using one three-way electromagnetic valve. Other designs and arrangements of the switching valve 140 may refer to the related art, and will not be described herein.

Alternatively, referring to fig. 1 and 2, in an electric mode and a manual mode, the airflow generator 120 may include a piston chamber 121 and a piston rod 122 disposed in the piston chamber 121, and the piston rod 122 is driven to reciprocate electrically or manually, thereby driving the first airflow chamber 210 to suck and exhaust air. Alternatively, the flow generator 120 may use a positive pressure ventilator and other prior art techniques capable of generating positive and negative pressure flows, which are not described in detail herein.

Alternatively, the atomizing device 110 may be a jet atomizer, an ultrasonic atomizer, or a vibrating screen mesh atomizer. For example, a vibrating mesh atomizer may be used to generate the aerosol. The size of aerosol particles generated by the vibration sieve pore atomizer depends on the diameter of the sieve pores, so that the particle size of the aerosol can be flexibly selected and controlled according to the needs, the particle size distribution of the aerosol is more concentrated, meanwhile, the vibration sieve pore atomizer can reduce the influence of ultrasonic vibration liquid heat production, the influence on inhaled medicines is less, and the atomization efficiency is higher.

It will be appreciated that an increase in the size of the aerosol particles will result in an increase in the mass of the aerosol particles and a reduction in the delivery distance, while also making it easier for the aerosol particles to collide with other aerosol particles or the walls of the airway during delivery, eventually leading to premature deposition of the aerosol particles and difficulty in delivery to the distal bronchi. For this reason, the median particle size of the aerosol generated by the atomization of the atomizing means 110 can be limited to a level of 1 μm to 5 μm, that is, the ratio of aerosol particles having a particle size of less than or equal to a certain value in the interval of 1 μm to 5 μm in the aerosol carried by the gas is half, thereby ensuring that most of the aerosol particles meet the requirements and facilitating the sufficient delivery of the aerosol to the small airways and alveoli at the tip.

Further, in the case that the atomizing device 110 employs a vibrating mesh atomizer, the particle size of the aerosol can be limited to a range of 1 μm to 5 μm, that is, the aerosol is generated by selecting a mesh with a pore diameter in a range of 1 μm to 5 μm, so as to further ensure that the particle size of the aerosol meets the requirement.

It should be noted that, due to the limited atomizing capability of the single atomizing device 110, a plurality of atomizing devices 110 may be arranged in parallel for simultaneous atomization in practical use.

Specifically, assuming that the inhalation amount of the user is 1L when inhaling slowly, the breathing process is that of inhaling 3s, shielding 1s, exhaling 3s, that is, the atomization device 110 needs to generate 1L of gas carrying aerosol in 7s, the total gas flow of the atomization device 110 is about 8L/min, so that many small portable atomizers commercially available at present are difficult to achieve the flow requirement, and therefore, it is considered that two atomization devices 110 of about 4L/min-5L/min are connected in parallel simultaneously for atomization. For example, the 2 atomizing devices 110 of 4L/min are used, the gas generated during exhalation is 0.4L, the gas generated and temporarily stored during inhalation and breath-hold are 0.53L, and the total gas delivered during exhalation is 0.93L, so that the requirements can be satisfied.

In addition, it may be noted that, in the air suction mode, the second air chamber 220 is closed by the switching valve 140, and the air generated by the atomizing device 110 is released to the second air chamber 220, which may cause the pressure of the second air chamber 220 to increase, thereby reducing the aerosol generating efficiency of the atomizing device 110, so that the concentration of the aerosol may not reach the requirement. To this end, the atomizing apparatus for increasing the deposition rate may further include a buffering means, which is communicated with the second gas chamber 220, for buffering the newly generated gas in the inhalation mode and releasing the gas to the first gas chamber 210 in the exhalation mode to maintain the pressure of the second gas chamber 220 stable.

For example, the buffer device may use the mist storage bag 130, and the volume of the mist storage bag 130 can be increased (i.e., fig. 2) and decreased (i.e., fig. 1) with the pressure change, so that the inside of the mist storage bag 130 and the second air chamber 220 communicating with the mist storage bag 130 are pressure-balanced with the external environment (i.e., the atmospheric pressure). The specific specification of the mist storage bag 130 may refer to the related prior art, and will not be described herein.

As indicated previously, excessive positive airway pressure may instead reduce the aerosol deposition effect, and for this purpose, the positive pressure may alternatively be set to be less than or equal to the maximum inhalation pressure of the user.

It can be appreciated that, on the one hand, when the positive pressure is set to be greater than the maximum suction pressure, the suction muscle of the user cannot adapt to the pressure of the airflow generator 120, so that breathing disorder or unsmooth breathing is caused, and further turbulence is more easily formed in the airflow, and the turbulence can cause aerosols carried by the airflow to collide with each other and deposit, so as to obstruct the aerosols from going deep into the airway, and not to be beneficial to the deposition of the aerosols in the bronchi; on the other hand, the normal breathing process of the human body is driven by the movements of the respiratory muscle diaphragm, and when in inspiration, the negative pressure enables gas to enter the respiratory system from the outside, so that excessively high inspiration synchronous pressurization can bring physiological uncomfortable reaction to a user, and the pharyngeal part can unconsciously generate contradicting actions, further aggravate respiratory disturbance or unsmooth breathing, obstruct aerosol from going deep into the airway and be unfavorable for the deposition of the aerosol in the bronchus.

In the inspiration process, the set positive pressure is limited not to exceed the maximum inspiration pressure of a user, so that the risk of turbulent flow of air flow in the oral cavity and the airway can be reduced, excessive deposition of aerosol in the oral cavity or the large airway is prevented, and the deposition of the aerosol in the small airway and alveoli is better promoted.

It is noted that there may be differences in maximum inspiratory pressure for different users, and that for users with dyspnea the maximum inspiratory pressure may be significantly lower than the normal maximum inspiratory pressure level, for which reason figure 4 shows the implementation steps of the control method of the aerosolization device in further embodiments of the present application. The atomizing apparatus control method shown in fig. 4 can also be performed by the embodiment of the atomizing apparatus for increasing the deposition rate shown in fig. 1 and 2.

Referring to fig. 4, the atomizing device control method may include:

step S410: the maximum suction pressure of the user is measured.

The method for determining the maximum suction pressure can refer to the related prior art, and will not be described herein.

Step S420: the atomizing device 110 atomizes and generates an aerosol.

Step S430: in response to the user exhaling, the aerosolization apparatus that increases the deposition rate switches to an exhaling mode, the first gas chamber 210 acquiring gas carrying aerosol from the second gas chamber 220;

Step S440: in response to a user inhaling, the aerosolization apparatus that increases the deposition rate switches to an inhaling mode, the first plenum 210 to set the positive pressure to deliver aerosol-carrying gas to the user.

The process from step S420 to step S440 corresponds to the process from step S310 to step S330, and the remaining technical details not mentioned in the embodiment shown in fig. 4 may refer to the embodiment shown in fig. 3, which will not be described herein.

Further, the set positive pressure may also be set to gradually increase from an initial value to a plateau value over a plurality of respiratory cycles.

By gradually increasing the set positive pressure, the device can help a user to gradually establish tolerance to the positive pressure state, avoid unconscious collision of the throat part of the user during inspiration, help the user to breathe deeply and slowly under the synchronous pressurization state of inspiration, further avoid turbulent flow of air flow in the oral cavity and the air channel, and further promote aerosol deposition in the small air channel and the alveoli.

Alternatively, to eliminate as much as possible the discomfort of the user in initially receiving positive airway pressure, and to encourage the user to build tolerance as soon as possible, the initial value may be set to any of 4cmH ₂ O to 8cmH ₂ O. At this pressure level, positive airway pressure only slightly produces an airway opening effect and is therefore not likely to cause discomfort to the user, providing a good basis for the user to build up tolerance.

Alternatively, the plateau value may be set to any of 10cmH ₂ O to 20cmH ₂ O, for example 10cmH ₂O、12cmH₂O、15cmH₂O、20cmH₂ O, etc. On the one hand, the platform value is larger than or equal to 10cmH ₂ O, the air passage opening effect of the atomization device can be guaranteed to meet the requirement, and on the other hand, the platform value is smaller than or equal to 20cmH ₂ O, the air flow speed can be prevented from being too fast, and the risk of turbulence is reduced.

The pressure rise curve from the initial value to the plateau value may be a simple linear curve, or a gradient curve, a parabolic curve, or the like, which is not particularly limited by the present application. It should be noted, however, that for different users with a branch, there may be a large difference in pressure tolerance, and the same pressure rise profile and pressure rise time may not be sufficient for the individual needs of the different users.

For this purpose, the set positive pressure is optionally increased by a set magnitude, the tolerance is determined after each inhalation, and increased again after the user establishes tolerance to the current pressure.

After inspiration, the user self-evaluates the coordination condition of this inspiration, such as whether the inspiration is smooth, whether the throat part has unconscious actions, etc., and evaluates the current tolerance condition by integrating the conditions, and if the tolerance condition is ideal, the positive pressure is set up again according to the set amplitude; if the tolerance condition is more general, keeping the current pressure to continue the next inhalation; if the tolerance is poor, the positive pressure is set slightly down (e.g., half the magnitude of the set down).

Alternatively, the user may be required to breathe deeply (breathing frequency below about 10 breaths/min) in combination with the restriction of the set positive pressure further reduces the risk of turbulence.

Specifically, due to the presence of the anatomic dead space, a portion of the gas inhaled by the user remains in the anatomic dead space each time. The relative proportion of this gas can be reduced by increasing the inspiration time, depth of breath, and decreasing the breathing rate (i.e., by breathing deeply or slowly) at the same minute ventilation to increase alveolar ventilation and facilitate aerosol deposition in bronchioles and alveoli. In addition, deep and slow breathing is beneficial to forming laminar flow, avoiding aerosol from colliding and depositing in the throat part, enabling the medicine to be conveyed farther and increasing the deposition rate of the lung.

The user actively breathes deeply and slowly while the atomizing device for increasing the deposition rate should be supplied with air synchronously so that the flow rate and pressure of the air flow are matched with the inhalation action of the user, thus the air flow is easier to form advection, turbulence is avoided, and simultaneously, the medicine is conveyed farther.

Alternatively, the air supply time of the atomizing device to increase the deposition rate may be set to 3.0s to 5.0s, that is, the duration of the inhalation pattern is 3s to 5s in one respiratory cycle. This is also the regular inspiration time range of the user in one breathing cycle of the deep slow breath, thereby playing a role in synchronizing with the user's inspiration. In the prior technical scheme of combining aerosol inhalation and positive pressure ventilation, the air supply time is often set to be 1s-1.2s according to the common practice of positive pressure mechanical ventilation, and the application overcomes the technical error.

Optionally, the control method of the atomization apparatus may further control the atomization device 110 to first atomize the bronchodilator, and then to atomize the set solution (such as a medical solution or hypertonic saline solution) so that the bronchodilator can dilate the small airway, and can also relieve the phenomena of sputum obstruction, airway wall inflammation and the like existing in the dilated lumen of the bronchus, which is helpful for the subsequent atomized solution to be more fully deposited in the small airway, and further improves the deposition rate of the aerosol in the dilated bronchus.

Illustratively, a bronchodilator such as albuterol + ipratropium bromide may first be nebulized for 5 minutes before nebulization therapy administration is initiated.

The present application more clearly illustrates the atomizing apparatus for improving deposition rate and the atomizing apparatus control method provided by the present application through the following specific examples. It is to be understood that the following description is exemplary only and is not intended to limit the application in any way. The present embodiment may also be replaced by or combined with the above-described corresponding technical features.

The atomization device for improving the deposition rate is provided with two atomization devices 110 (ultrasonic atomizers are adopted), the gas flow rate generated by each ultrasonic atomizer is divided into three gears of a low gear 4L/min, a middle gear 5L/min and a high gear 6L/min, the three gears correspond to the gears 120 of the airflow generator of a low gear 10cm H ₂ O, a middle gear 14cm H ₂ O and a high gear 18cm H ₂ O respectively, and the user exhales for 3 seconds and inhales for 3 seconds each time when atomizing, and holds the breath for 1 second after inhaling.

The positive pressure is first applied starting from 6cmH ₂ O, then the pressure is increased to 10cm H ₂ O at the lower end and maintained, if the feedback tolerance of the user is better, the pressure is increased to 14cm H ₂ O at the middle end, and the pressure can be increased to 18cm H ₂ O at the upper end.

When a user exhales, the respiration sensor 150 senses an expiration signal, the exhaust passage is closed, the intake passage is opened, and gas newly generated by the atomizing device 110 and having aerosol in the mist storage bag 130 is stored in the first air chamber 210 under the driving of the negative pressure generated by the air flow generator 120.

In expiration time, the gas generated by the 2 ultrasonic atomizers is low-grade 0.4L, medium-grade 0.5L and high-grade 0.6L. The mist storage bag 130 stores 0.53L low, 0.67L medium and 0.8L high gas. The gas having the low stage 0.93L, the medium stage 1.17L, and the high stage 1.4L is stored in the first gas chamber 210 when exhaling.

When the user inhales, the respiration sensor 150 senses an inhalation signal, the exhaust passage is opened, the intake passage is closed, and the aerosol in the first air chamber 210 is delivered into the user's lungs under the urging of the airflow generator 120. Simultaneously, the user can inhale slowly for 3 seconds, and hold breath for 1 second after inhaling. While the gas (low stage 0.53L, medium stage 0.67L, high stage 0.8L) generated by the atomizing device 110 is stored in the mist storage bag 130.

In the operation process, the atomization device for improving the deposition rate prompts the operation state (such as prompting 'inhaling, 1 second, 2 seconds and 3 seconds') through the sound prompting device so as to help a user to consciously control the breathing time, and avoid excessively short time or overtime, so that the gas volume is greatly deviated.

The atomization device for improving the deposition rate and the atomization device control method provided by the application are verified through the following experiments. It should be emphasized that although the present application uses the nebulized therapeutic drug in the following experiments, the nebulizing device and the nebulizing device control method of the present application aim to achieve the effect of increasing the deposition rate by controlling the nebulizing device, and the nebulizing device control method is simply used for controlling the nebulizing device, but may of course be used for non-therapeutic purposes in other situations.

1. Subject collection

1. General data

48 Patients diagnosed with bronchiectasis from 3 months 2022 to 3 months 2024 were divided into control group 1-6 and experimental group, control group 1 into 12 cases, with average age of 46 years; control group 2 into group 8, mean age 51 years; control group 3 into group 8, average age: age 48; control group 4 into group 3, average age: 54 years old; control group 5 into group 3, average age: age 51; control group 6 into group 2, average age: age 40. Experimental group 12 cases, average age: age 46. The general data comparison differences of the gender, age, body mass index and the like of the patients in each group have no statistical significance (P > 0.05) and are comparable.

Inclusion criteria:

experimental subjects symbolized the informed consent of all patients.

Exclusion criteria:

1. Allergy to nebulized therapeutic drugs;

2. Hemoptysis;

3. Hypoxia;

4. severe bronchial asthma;

5. patients with other basic diseases such as acute myocardial infarction cannot tolerate aerosol inhalation.

Comparative example 1: atomization is carried out by a traditional atomization device

Control group 1: a jet nebulizer (ohmmeter C28) was used to nebulize 12 patients without applying positive pressure.

Control group 2: an ultrasonic nebulizer (VGR-001A) was used to nebulize 8 patients without applying positive pressure.

Control group 3: using a vibrating mesh nebulizer (yu shen M102), nebulization was performed on 8 patients without applying positive pressure.

The atomization method comprises the following steps: 2.5ml of bronchodilator, buride +2.5ml of physiological saline, was first nebulized for 5 minutes, then ¹⁸ F-FNA labeled 7% hypertonic saline, 5ml, was nebulized for 10 minutes, and PET-CT scan was performed to observe the distribution of the aerosol in the lungs of the patient.

Comparative example 2: atomizing by combining traditional atomizing device with positive pressure ventilation

Control group 4: the nebulization was performed on 3 patients based on the CPAP method using a vibrating mesh nebulizer (fish-jump M102) in combination with a bi-level positive pressure ventilator (philips BiPAP a 40), with ventilation parameters of: CPAP 12 cmH ₂ O.

Control group 5: the nebulization was performed on 3 patients based on the BiPAP method using a vibrating mesh nebulizer (fish-jump M102) in combination with a bi-level positive pressure ventilator (philips BiPAP a 40), with ventilation parameters of: IPAP 14cmH ₂O、EPAP 4cmH₂ O, inspiration time 1.2s.

Control group 6: using a jet nebulizer (ohmmeter c 28) in combination with a positive pressure ventilator (The MeatNeb System), nebulized inhalation was performed on 2 patients based on continuous positive pressure ventilation and high frequency oscillatory ventilation methods, with ventilation parameters of: continuous positive pressure ventilation for 2.5min and high frequency oscillation ventilation for 2.5min.

Specifically, the nebulizer device was connected to a positive pressure ventilator, 2.5ml of bronchodilator, and 2.5ml of physiological saline were first nebulized for 5 minutes, then ¹⁸ F-FNA labeled 7% hypertonic saline was nebulized for 10 minutes, and PET-CT scan was performed to observe the distribution of the aerosol in the lungs of the patient.

The experimental group uses the atomization device for improving the deposition rate and the atomization device control method provided by the application, the atomization device 110 uses a vibration sieve pore atomizer (fish-eye M102) to perform atomization inhalation on 12 patients, and the ventilation parameters are as follows: the air delivery time (i.e., the duration of the inhalation mode) is 3-5s; the patient's pneumatic pressure (i.e., the set positive pressure) is gradually increased from 4cmH ₂ O to a plateau value of 10cmH ₂ O (less than or equal to the patient's maximum inspiratory pressure) in five minutes.

Specifically, 2.5ml of bronchodilator may be nebulized with 2.5ml of physiological saline for 5 minutes, and then ¹⁸ F-FNA labeled 7% hypertonic saline for 5ml of hypertonic saline for 10 minutes, and PET-CT scanning is performed to observe the distribution of the aerosol in the lungs of the patient.

3. Observation index

Based on the development results, the deposition distribution of the aerosol in the dilated bronchi was compared.

2. Therapeutic results

The results of comparing the distribution of the drug in the bronchi before and after the treatment of the patients are shown in Table 1.

Table 1: aerosol deposition status observation meter

Wherein, the significant means that the whole lung field is evenly developed, the medium means that 1/2-2/3 lung field is developed, and the slight means that less than 1/10 lung field is developed.

Comparing the above experimental data, it can be seen that the deposition distribution of the aerosol can be significantly improved by using the atomization device and the atomization device control method for improving the deposition rate provided by the application, so that the aerosol is sufficiently deposited in the dilated bronchi.

The present application illustratively extracts the following examples from experimental data, and the control method of the atomizing device provided by the present application can be better understood by means of the following examples.

Example 1

This example is from control group 1, and the effect of deposition based on the conventional nebulization (jet nebulization) was evaluated for patients with symptoms of bronchiectasis.

The experimental object:

a 64 year old bronchiectasis patient, left lower lobe bronchiectasis.

Experimental results:

Fig. 5 shows the experimental results of example 1, and it is evident that the aerosol is mainly deposited in the bronchi without dilation, and is substantially deposited in the bronchi without dilation (lower left lobe area in the figure).

Example 2

This example was from control group 2, and the effect of deposition based on the conventional nebulization method (ultrasonic nebulization) was evaluated for patients with symptoms of bronchiectasis.

The experimental object:

A 55 year old bronchodilator patient, right middle lobe and left lingual lobe bronchodilators.

Experimental results:

Fig. 6 shows the experimental results of example 2, and it is evident that the aerosol is mainly deposited in the bronchi without dilation, and is substantially deposited in the bronchi without dilation (right middle lobe and left lingual lobe areas in the figure).

Example 3

This example was from control group 3, and the effect of deposition based on the conventional nebulization method (vibrating mesh nebulization) was evaluated for patients with symptoms of bronchiectasis.

The experimental object:

A 66 year old bronchiectasis patient, left lingual lobe and left inferior lobe bronchiectasis.

Experimental results:

fig. 7 shows the experimental results of example 3, and it is evident that the aerosol is mainly deposited in the bronchi without dilation, and is substantially deposited in the bronchi without dilation (left lingual lobe and left inferior lobe areas in the figure).

Example 4

This example is from control group 5, and the effect of nebulization based on bi-level positive airway pressure (BiPAP) on deposition at dilated bronchial sites was evaluated for patients with bronchodilators.

The experimental object:

a patient with bronchiectasis at 17 years old, with bronchiectasis in the lower left lung.

Experimental results:

Fig. 8 shows the experimental results of example 4, and it is evident that aerosol deposition is mainly observed in the oropharynx and large airways, and that also part of the aerosol is swallowed into the stomach, with substantially no aerosol deposition observed in both the unexpanded bronchi and the expanded bronchi.

Example 5

This example is from the experimental group, and the deposition effect of the control method of the atomizing device provided by the present application was evaluated for patients with symptoms of bronchiectasis.

The experimental object:

A 20 year old bronchodilatory patient, left lower lung bronchodilatory.

Experimental results:

Fig. 9 shows the experimental results of example 5, and it can be observed that there is significant aerosol deposition in the dilated bronchi, with a significant increase in aerosol deposition rate.

The present application further evaluates the therapeutic effect of using the control method of the atomizing device provided by the present application, for which the following example 6 is provided.

Example 6

The therapeutic effect of the control method of the nebulizing device provided by the application was evaluated for patients with symptoms of bronchiectasis.

The experimental object:

A 28 year old bronchodilatory patient, left lower lung bronchodilatory.

Experimental protocol:

the atomization device for improving the deposition rate and the atomization device control method provided by the application are adopted for atomization treatment for 1 month. 2.5ml of bronchodilator, cobicistat +2.5ml of physiological saline, is first nebulized for 5 minutes, and then 5ml of 7% hypertonic saline is nebulized for 15 minutes, twice daily.

Experimental results:

Fig. 10 shows the experimental results of example 6, showing the lung condition of a patient before and one month after nebulization, from which it can be observed that a large number of mucus plugs are present in the dilated bronchi before nebulization treatment, and that the dilated bronchi are substantially cleared after nebulization treatment.

In the description of the present specification, reference to the terms "one embodiment," "some embodiments," "illustrative embodiments," "examples," "specific examples," or "some examples," etc., means that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the application. In this specification, schematic representations of the above terms do not necessarily refer to the same embodiments or examples. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples.

In some alternative embodiments, the functions/acts noted in the block diagrams may occur out of the order noted in the operational illustrations. For example, two blocks shown in succession may in fact be executed substantially concurrently or the blocks may sometimes be executed in the reverse order, depending upon the functionality/acts involved. Furthermore, the embodiments presented and described in the flowcharts of the present application are provided by way of example in order to provide a more thorough understanding of the technology. The disclosed methods are not limited to the operations and logic flows presented herein. Alternative embodiments are contemplated in which the order of various operations is changed, and in which sub-operations described as part of a larger operation are performed independently.

While embodiments of the present application have been shown and described, it will be understood by those of ordinary skill in the art that: many changes, modifications, substitutions and variations may be made to the embodiments without departing from the spirit and principles of the application, the scope of which is defined by the claims and their equivalents.

Claims (16)

1. An aerosol apparatus for increasing a deposition rate, the aerosol apparatus being switchable between an inhalation mode and an exhalation mode, the aerosol apparatus comprising:

The air chamber comprises a first air chamber and a second air chamber, the first air chamber is communicated with the second air chamber through an air inlet channel, and the first air chamber is used for being communicated with a user through an air outlet channel;

The atomization device is communicated with the second air chamber and is used for supplying gas carrying aerosol to the second air chamber;

A switching valve configured to open the intake passage and close the exhaust passage in the exhalation mode and to close the intake passage and open the exhaust passage in the inhalation mode;

The air flow generator is communicated with the first air chamber, and in the expiration mode, the air flow generator drives the first air chamber to feed air from the second air chamber, and in the inspiration mode, the air flow generator drives the first air chamber to set positive air feeding to a user.

2. The deposition rate enhancing misting apparatus of claim 1 comprising a breath sensor disposed at an outlet of said exhaust passage for detecting a breath condition of a user to allow said deposition rate enhancing misting apparatus to switch between an inhalation mode and an exhalation mode in response to the breath condition.

3. The atomizing apparatus for increasing a deposition rate according to claim 2, wherein the switching valve includes a first solenoid valve provided in the exhaust passage and a second solenoid valve provided in the intake passage.

4. The deposition rate enhancing atomizing apparatus of claim 2, wherein the gas flow generator comprises a piston chamber and a piston rod disposed in the piston chamber, the piston rod reciprocating to drive the first gas chamber to inhale and exhale.

5. The deposition rate enhancing atomizing apparatus of claim 1, wherein the deposition rate enhancing atomizing apparatus comprises a mist storage bag, the mist storage bag being in communication with the second air chamber, the mist storage bag being capable of increasing and decreasing in volume with a change in pressure to maintain the pressure of the second air chamber stable.

6. The atomizing apparatus for improving a deposition rate according to claim 1, wherein the median particle diameter of the aerosol produced by atomization by the atomizing means is 1 to 5 μm.

7. The atomizing apparatus for increasing a deposition rate according to claim 1 or 6, wherein the atomizing device is a vibrating screen mesh atomizer, a jet atomizer, or an ultrasonic atomizer.

8. The deposition rate enhancing atomizing apparatus of claim 7, wherein the deposition rate enhancing atomizing apparatus is provided with a plurality of the atomizing devices in parallel.

9. An atomizing apparatus control method for controlling the atomizing apparatus for increasing a deposition rate according to any one of claims 1 to 8, comprising:

the atomizing device atomizes and generates aerosol;

in response to exhalation by a user, the increased deposition rate aerosolization apparatus switches to the exhalation mode, the first gas chamber capturing aerosol-carrying gas from the second gas chamber;

in response to a user inhaling, the deposition rate enhancing atomizing apparatus switches to the inhaling mode, the first plenum being configured to deliver aerosol-carrying gas to the user in a positive pressure.

10. The atomizing apparatus control method according to claim 9, wherein the set positive pressure is less than or equal to a maximum suction pressure of a user.

11. The atomizing apparatus control method of claim 10, further comprising determining a maximum suction pressure of the user.

12. The atomizing apparatus control method according to claim 10, wherein the set positive pressure is gradually increased from an initial value to a plateau value over a plurality of respiratory cycles.

13. The atomizing apparatus control method according to claim 12, wherein the plateau value is set to any value of 10cmH ₂ O to 20cmH ₂ O.

14. The atomizing apparatus control method according to claim 13, wherein the initial value is set to any value of 4cmH ₂ O to 8cmH ₂ O.

15. The atomizing device control method according to any one of claims 12 to 14, wherein the set positive pressure is increased in accordance with a set magnitude, the tolerance is judged after each inhalation, and the increase is again made after the user establishes the tolerance to the current pressure.

16. The atomizing apparatus control method according to claim 9, wherein the duration of the inhalation pattern is 3s to 5s in one respiratory cycle.